JPH05501202A - インフルエンザ菌b型の外膜タンパク質p1およびペプチド類 - Google Patents
インフルエンザ菌b型の外膜タンパク質p1およびペプチド類Info
- Publication number
- JPH05501202A JPH05501202A JP2514680A JP51468090A JPH05501202A JP H05501202 A JPH05501202 A JP H05501202A JP 2514680 A JP2514680 A JP 2514680A JP 51468090 A JP51468090 A JP 51468090A JP H05501202 A JPH05501202 A JP H05501202A
- Authority
- JP
- Japan
- Prior art keywords
- protein
- haemophilus influenzae
- peptide
- peptides
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 46
- 102000004196 processed proteins & peptides Human genes 0.000 title claims description 19
- 101710167679 Outer membrane protein P1 Proteins 0.000 title claims description 5
- 241000606768 Haemophilus influenzae Species 0.000 title claims 11
- 229940045808 haemophilus influenzae type b Drugs 0.000 title claims 7
- 108090000623 proteins and genes Proteins 0.000 claims description 63
- 102000004169 proteins and genes Human genes 0.000 claims description 34
- 239000013598 vector Substances 0.000 claims description 14
- 101000846901 Drosophila melanogaster Fat-body protein 1 Proteins 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 230000014509 gene expression Effects 0.000 claims description 10
- 102000014914 Carrier Proteins Human genes 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 229960005486 vaccine Drugs 0.000 claims description 8
- 108010078791 Carrier Proteins Proteins 0.000 claims description 7
- 239000013612 plasmid Substances 0.000 claims description 7
- 108010060123 Conjugate Vaccines Proteins 0.000 claims description 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 5
- 229940031670 conjugate vaccine Drugs 0.000 claims description 5
- 150000004676 glycans Polymers 0.000 claims description 5
- 230000002163 immunogen Effects 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 206010022000 influenza Diseases 0.000 claims description 3
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 150000004804 polysaccharides Polymers 0.000 claims description 2
- 229940047650 haemophilus influenzae Drugs 0.000 claims 4
- 241000606790 Haemophilus Species 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 229940023143 protein vaccine Drugs 0.000 claims 1
- 230000001131 transforming effect Effects 0.000 claims 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 15
- 239000000562 conjugate Substances 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
- 230000004927 fusion Effects 0.000 description 9
- 241000699666 Mus <mouse, genus> Species 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 108020001507 fusion proteins Proteins 0.000 description 7
- 102000037865 fusion proteins Human genes 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 230000003053 immunization Effects 0.000 description 6
- 238000002649 immunization Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 239000000020 Nitrocellulose Substances 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 230000005847 immunogenicity Effects 0.000 description 5
- 229920001220 nitrocellulos Polymers 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 4
- 239000011534 wash buffer Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 244000025254 Cannabis sativa Species 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 206010013023 diphtheria Diseases 0.000 description 3
- 238000002523 gelfiltration Methods 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 241000283707 Capra Species 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 102000016607 Diphtheria Toxin Human genes 0.000 description 2
- 108010053187 Diphtheria Toxin Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101710116435 Outer membrane protein Proteins 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 206010043376 Tetanus Diseases 0.000 description 2
- 102100037697 Uridylate-specific endoribonuclease Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- JRXXLCKWQFKACW-UHFFFAOYSA-N biphenylacetylene Chemical compound C1=CC=CC=C1C#CC1=CC=CC=C1 JRXXLCKWQFKACW-UHFFFAOYSA-N 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011026 diafiltration Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000009610 hypersensitivity Effects 0.000 description 2
- 102000035118 modified proteins Human genes 0.000 description 2
- 108091005573 modified proteins Proteins 0.000 description 2
- 239000000863 peptide conjugate Substances 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 101150082998 pi gene Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011552 rat model Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 101150028074 2 gene Proteins 0.000 description 1
- YCTIVQHRJIAMKZ-UHFFFAOYSA-N 2-amino-4-(2-iodoacetyl)benzoic acid Chemical compound NC1=CC(C(=O)CI)=CC=C1C(O)=O YCTIVQHRJIAMKZ-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- YRNWIFYIFSBPAU-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-n,n-dimethylaniline Chemical compound C1=CC(N(C)C)=CC=C1C1=CC=C(N(C)C)C=C1 YRNWIFYIFSBPAU-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 240000006108 Allium ampeloprasum Species 0.000 description 1
- 235000005254 Allium ampeloprasum Nutrition 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101001100194 Drosophila melanogaster Heterogeneous nuclear ribonucleoprotein 87F Proteins 0.000 description 1
- WZKSXHQDXQKIQJ-UHFFFAOYSA-N F[C](F)F Chemical compound F[C](F)F WZKSXHQDXQKIQJ-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000764773 Inna Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 206010027202 Meningitis bacterial Diseases 0.000 description 1
- 101000987582 Mus musculus Perforin-1 Proteins 0.000 description 1
- 101710107904 NADH-ubiquinone oxidoreductase subunit 9 Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 101710194807 Protective antigen Proteins 0.000 description 1
- 101710132845 Protein P1 Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- -1 act + 工mmun Chemical compound 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 230000002788 anti-peptide Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 201000009904 bacterial meningitis Diseases 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010252 digital analysis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 108010026228 mRNA guanylyltransferase Proteins 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 102000013415 peroxidase activity proteins Human genes 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229940031937 polysaccharide vaccine Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 201000005484 prostate carcinoma in situ Diseases 0.000 description 1
- 229940116540 protein supplement Drugs 0.000 description 1
- 235000005974 protein supplement Nutrition 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 229940126577 synthetic vaccine Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/285—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pasteurellaceae (F), e.g. Haemophilus influenza
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (16)
- 1.第1図の誘導アミノ酸配列またはそれに実質的に相同の誘導アミノ酸配列を 有するインフルエンザ菌(Haemophilus influenzzae) b型由来遺伝子工字処理された外膜タンパク質P1。
- 2.前記インフルエンザ菌(Haemophilus influenzae) b型がMinnA株(OMPサブタイブ1H)、8358株(OMPサブタイブ 6U)および1613株(OMPサブタイブ3L)から選択されることを特徴と する請求の範囲第1項に記載のタンパク質。
- 3.第1図のヌクレオチド配列またはそれに実質的に相同のものを有する遺伝子 の断片または変異体であり、かつ、ベクター中で発現されると、インフルエンザ 菌(Haemophilus influenzae)b型の天然タンパク質の 免疫特性の少なくとも部分を保有するタンパク質またはペプチドを提供する遺伝 子。
- 4.インフルエンザ菌(Haemophilus influenzae)b型 のゲノム中に染色体的に再組み込みされた変異P1遺伝子であることを特徴とす る請求の範囲第3項に記載の遺伝子。
- 5.請求の範囲第3項または第4項に記載の遺伝子から産生された遺伝子工学処 環されたタンパク質またはペプチド。
- 6.インフルエンザ菌(Haemophilus influenzae)b型 の天然P1タンパク質の免疫特性の少なくとも部分を保有するタンパク質または ペプチド。
- 7.有機体からの発現によって産生される請求の範囲第6項に記載のタンパク質 またはペプチド。
- 8.合成的に産生される請求の範囲第6項に記載のタンパク質またはペプチド。
- 9.インフルエンザ(Haemophilus influenzae)b型に 対するワクチンで、薬剤学的に許容できるそのための担体中の請求の範囲第6項 に記載のタンパク質またはペプチドからなることを特徴とするワクチン。
- 10.前記タンパク質またはペプチドが担体タンパク質に結合している請求の範 囲第9項に記載のワクチン。
- 11.インフルエンザ菌(Haemophilus influenzae)b 型に対する結合ワクチンで、ヘモフイルス(Haemophilus)生物体の 莢膜多糖部分に結合した請求の範囲第1項に記載のタンパク質からなるワクチン 。
- 12.放熱P1タンパク質のアミノ酸残基60から88、165から193、1 89から218、226から253、248から283、307から331、3 39から370、384から412、または400から437に対応するアミノ 酸配列を有する免疫原性合成ペプチド。
- 13.請求の範囲第12項に記載の合成ペプチドおよびそのための担体タンパク 質からなる結合物。
- 14.アミノ酸航の点でインフルエンザ菌(インフルエンザ菌(Haemoph ilus influenzae)b型の天然P1タンパク質に対応するタンパ ク質をベクター中で産生する方法で、 pRSM291,pRSM734およびpRSM793から選択されたP1遺伝 子を含有するプラスミドを構築すること、前記プラスミドで有機体を形質転換す ること、および前記形質転換有機体からP1タンパク質を産生することからなる 方法。
- 15.インフルエンザ菌(Haemophilusinfluenzae)b型 の生物体的に純粋な天然のP1タンパク質。
- 16.インフルエンザ菌(Haemophilus influenzae)b 型が原因の疾患による感染の診断におれる請求の範囲第6項に記載のタンパク質 の使用。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB898924473A GB8924473D0 (en) | 1989-10-31 | 1989-10-31 | Outer membrane protein p1 and peptides of haemophilus influenzae b |
GB8924473.5 | 1989-10-31 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH05501202A true JPH05501202A (ja) | 1993-03-11 |
JP2644625B2 JP2644625B2 (ja) | 1997-08-25 |
Family
ID=10665452
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2514680A Expired - Lifetime JP2644625B2 (ja) | 1989-10-31 | 1990-10-31 | インフルエンザ菌b型の外膜タンパク質p1およびペプチド類 |
Country Status (11)
Country | Link |
---|---|
US (1) | US5985288A (ja) |
EP (1) | EP0500576B1 (ja) |
JP (1) | JP2644625B2 (ja) |
AT (1) | ATE126701T1 (ja) |
CA (1) | CA2072095C (ja) |
DE (1) | DE69021886T2 (ja) |
DK (1) | DK0500576T3 (ja) |
ES (1) | ES2079493T3 (ja) |
GB (1) | GB8924473D0 (ja) |
GR (1) | GR3018208T3 (ja) |
WO (1) | WO1991006652A1 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5843463A (en) * | 1990-12-21 | 1998-12-01 | Antexbiologics, Inc. | Adhesin-oligosaccharide conjugate vaccine for Haemophilus influenzae |
ES2131066T3 (es) * | 1990-12-21 | 1999-07-16 | Antex Biolog Inc | Vacuna de conjugacion de oligosacarido con adhesina para hi(haemophilus influenzae). |
GB9202219D0 (en) * | 1992-02-03 | 1992-03-18 | Connaught Lab | A synthetic heamophilus influenzae conjugate vaccine |
GB9224584D0 (en) | 1992-11-23 | 1993-01-13 | Connaught Lab | Use of outer membrane protein d15 and its peptides as vaccine against haempohilus influenzae diseases |
US5681570A (en) * | 1995-01-12 | 1997-10-28 | Connaught Laboratories Limited | Immunogenic conjugate molecules |
US6592776B1 (en) | 1997-07-28 | 2003-07-15 | Cabot Microelectronics Corporation | Polishing composition for metal CMP |
US7052860B2 (en) | 2001-11-28 | 2006-05-30 | University Of Florida Research Foundation | Identification of Actinobacillus actinomycetemcomitans antigens for use in the diagnosis, treatment, and monitoring of periodontal diseases |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63190896A (ja) * | 1986-12-31 | 1988-08-08 | デ・スタート・デル・ネーデルランデン | 新規なオリゴ糖、免疫原およびワクチン、ならびにそのようなオリゴ糖、免疫原およびワクチンの製造方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4554101A (en) * | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
US4673574A (en) * | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
US4496538A (en) * | 1982-07-06 | 1985-01-29 | Connaught Laboratories, Inc. | Haemophilus influenzae b polysaccharide-diphtheria toxoid conjugate vaccine |
GB9202219D0 (en) * | 1992-02-03 | 1992-03-18 | Connaught Lab | A synthetic heamophilus influenzae conjugate vaccine |
-
1989
- 1989-10-31 GB GB898924473A patent/GB8924473D0/en active Pending
-
1990
- 1990-10-31 CA CA002072095A patent/CA2072095C/en not_active Expired - Lifetime
- 1990-10-31 JP JP2514680A patent/JP2644625B2/ja not_active Expired - Lifetime
- 1990-10-31 EP EP90915737A patent/EP0500576B1/en not_active Expired - Lifetime
- 1990-10-31 WO PCT/CA1990/000374 patent/WO1991006652A1/en active IP Right Grant
- 1990-10-31 DK DK90915737.2T patent/DK0500576T3/da active
- 1990-10-31 DE DE69021886T patent/DE69021886T2/de not_active Expired - Lifetime
- 1990-10-31 ES ES90915737T patent/ES2079493T3/es not_active Expired - Lifetime
- 1990-10-31 AT AT90915737T patent/ATE126701T1/de not_active IP Right Cessation
-
1995
- 1995-06-07 US US08/472,172 patent/US5985288A/en not_active Expired - Lifetime
- 1995-11-24 GR GR950401154T patent/GR3018208T3/el unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS63190896A (ja) * | 1986-12-31 | 1988-08-08 | デ・スタート・デル・ネーデルランデン | 新規なオリゴ糖、免疫原およびワクチン、ならびにそのようなオリゴ糖、免疫原およびワクチンの製造方法 |
Also Published As
Publication number | Publication date |
---|---|
EP0500576B1 (en) | 1995-08-23 |
GR3018208T3 (en) | 1996-02-29 |
WO1991006652A1 (en) | 1991-05-16 |
DK0500576T3 (da) | 1995-09-25 |
ATE126701T1 (de) | 1995-09-15 |
ES2079493T3 (es) | 1996-01-16 |
CA2072095A1 (en) | 1991-05-01 |
DE69021886D1 (de) | 1995-09-28 |
DE69021886T2 (de) | 1996-01-11 |
CA2072095C (en) | 1999-09-28 |
GB8924473D0 (en) | 1989-12-20 |
US5985288A (en) | 1999-11-16 |
EP0500576A1 (en) | 1992-09-02 |
JP2644625B2 (ja) | 1997-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5773572A (en) | Fragments of prion proteins | |
KR100500782B1 (ko) | 융합단백질로서의 이종성 항원유전자 발현 시스템 | |
US5843464A (en) | Synthetic chimeric fimbrin peptides | |
Rothbard et al. | Antibodies to peptides corresponding to a conserved sequence of gonococcal pilins block bacterial adhesion. | |
EP0759941B1 (en) | Heterodimer polypeptideimmunogen carrier composition and method for their use | |
JP2003529319A (ja) | HIV−1gp41を標的化する広範に中和する抗体を誘発する方法 | |
Takai et al. | Prokaryotic expression of the thyrotropin receptor and identification of an immunogenic region of the protein using synthetic peptides | |
EP0787139B1 (en) | Synthetic peptides and vaccines comprising same | |
JP2002533125A (ja) | 改変hivenvポリペプチド | |
JP3060504B2 (ja) | ワクチン | |
AU714423B2 (en) | Carrier protein having an adjuvant effect, immunogenic complex containing same, preparation method therefor, nucleotide sequence and vaccine | |
WO1991013909A1 (en) | Synthetic polypeptides | |
Kraus et al. | Vimentin-cross-reactive epitope of type 12 streptococcal M protein | |
US20190117756A1 (en) | Immunogenic Compositions and Vaccines Derived From Bacterial Surface Receptor Proteins | |
JPH02503916A (ja) | Hivエンベロープ蛋白質に関連する合成ペプチド | |
JPH05501202A (ja) | インフルエンザ菌b型の外膜タンパク質p1およびペプチド類 | |
EP0166548A2 (en) | Broad spectrum vaccine against gonorrhea | |
CA2006587C (en) | Membrane proteins and peptides of haemophilus influenzae type b | |
WO1993021218A1 (en) | Synthetic polypeptides derived from the hiv envelope glycoprotein | |
WO1994002508A2 (en) | Polypeptide antigens of mycobacterium bovis | |
US5916562A (en) | Membrane proteins and peptides of haemophilus influenzae type B | |
HOUSTON et al. | Patent 2190494 Summary |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090502 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100502 Year of fee payment: 13 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110502 Year of fee payment: 14 |
|
EXPY | Cancellation because of completion of term | ||
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110502 Year of fee payment: 14 |